NeuroSearch announces that today 530,745 new shares of DKK 20 nominal value
each, corresponding to a total nominal capital increase of DKK 10,614,900, have
been registered with the Danish Commerce and Companies Agency. As announced in
announcement no. 03-09 from 17 February 2009, all the new shares have been
subscribed by Eli Lilly and Company at a price of DKK 187 per share of DKK 20
nominal value each.

The net proceeds to NeuroSearch from the directed offering amount to DKK 99.2
million.

The 530,745 new shares will be issued without pre-emption rights for the
company's current shareholders. The issue has been decided by the board of
directors in NeuroSearch on the basis of Article 5 of the company's Articles of
Association authorising the board of directors to increase the share capital of
the company. The new shares will rank pari passu with and have the same rights
as the existing shares in the company.

Following registration of the new shares, NeuroSearch's share capital amounts
to DKK 325,480,600 (16,274,030 shares of DKK 20 nominal value each).

The new shares will be admitted to trading and official listing on Nasdaq OMX
Copenhagen on 6 March 2009 under the ISIN of NeuroSearch's existing shares
(ISIN DK0010224666).


Flemming Pedersen
CEO


Contact persons:
Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4460 8212 or +45 4017 5103

NeuroSearch - Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq
OMX Copenhagen. The company's core business covers the development of novel
drugs, based on a broad and well-established drug discovery platform focusing
on ion channels and CNS disorders. A substantial share of NeuroSearch's
activities is partner financed through an alliance with Eli Lilly and Company
and collaborations with GlaxoSmithKline (GSK) and Abbott. The drug pipeline
comprises 9 clinical (Phase I-III) development programmes: ACR16 for
Huntington's disease (Phase III), tesofensine for obesity and type 2 diabetes
(Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott,
ACR325 for Parkinson's disease (Phase II in preparation) and bipolar disorder
(Phase II ready), ABT-107 and ABT-560 for the treatment of various CNS
disorders - both (Phase I) in collaboration with Abbott, ACR343 for Parkinson's
disease (Phase I) and NSD-788 for anxiety/depression (Phase I). In addition,
NeuroSearch has a broad portfolio of preclinical drug candidates and holds
equity interests in several biotech companies.

fonds.06-09 - lilly closing - uk_final.pdf